182 related articles for article (PubMed ID: 624854)
1. Topical treatment of vaccinia virus infection with an interferon inducer in rabbits.
Levy HB; Lvovsky E
J Infect Dis; 1978 Jan; 137(1):78-81. PubMed ID: 624854
[TBL] [Abstract][Full Text] [Related]
2. Cortisol induction by poly ICLC: implications for clinical trials of interferon.
Bever CT; McFarland HF; Levy HB; McFarlin DE
Ann Neurol; 1988 Feb; 23(2):196-9. PubMed ID: 2454067
[TBL] [Abstract][Full Text] [Related]
3. A comparison of interferon responses to poly ICLC in males and females.
Bever CT; McFarlin DE; Levy HB
J Interferon Res; 1985; 5(3):423-8. PubMed ID: 2414373
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator.
Peters CJ; Reynolds JA; Slone TW; Jones DE; Stephen EL
Antiviral Res; 1986 Aug; 6(5):285-97. PubMed ID: 2429616
[TBL] [Abstract][Full Text] [Related]
5. Topical polyriboinosinic-polyribocytidylic acid complex in the treatment of recurrent genital herpes.
Crane LR; Levy HB; Lerner AM
Antimicrob Agents Chemother; 1982 Mar; 21(3):481-5. PubMed ID: 7049075
[TBL] [Abstract][Full Text] [Related]
6. [Effect of interferon inducer (poly ICLC) in the treatment of malignant brain tumor (author's transl)].
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
No To Shinkei; 1982 Mar; 34(3):267-73. PubMed ID: 7093065
[TBL] [Abstract][Full Text] [Related]
7. Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.
Kende M; Lupton HW; Rill WL; Levy HB; Canonico PG
Antimicrob Agents Chemother; 1987 Jul; 31(7):986-90. PubMed ID: 3662477
[TBL] [Abstract][Full Text] [Related]
8. Phase I-II trials of poly(ICLC) in malignant brain tumor patients.
Nakamura O; Shitara N; Matsutani M; Takakura K; Machida H
J Interferon Res; 1982; 2(1):1-4. PubMed ID: 6180095
[TBL] [Abstract][Full Text] [Related]
9. Treatment of recurrent laryngeal papillomatosis with an artificial interferon inducer (poly ICLC).
Leventhal BG; Kashima H; Levine AS; Levy HB
J Pediatr; 1981 Oct; 99(4):614-6. PubMed ID: 7277106
[No Abstract] [Full Text] [Related]
10. Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys.
Puri SK; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1996 Jan; 16(1):49-52. PubMed ID: 8640451
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice.
Kende M
J Biol Response Mod; 1985 Oct; 4(5):503-11. PubMed ID: 2416883
[TBL] [Abstract][Full Text] [Related]
12. Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits.
Gatmaitan BG; Legaspi RC; Levy HB; Lerner AM
Antimicrob Agents Chemother; 1980 Jan; 17(1):49-54. PubMed ID: 7352750
[TBL] [Abstract][Full Text] [Related]
13. Preliminary trial of poly ICLC in chronic progressive multiple sclerosis.
Bever CT; Salazar AM; Neely E; Ferraraccio BE; Rose JW; McFarland HF; Levy HB; McFarlin DE
Neurology; 1986 Apr; 36(4):494-8. PubMed ID: 3960323
[TBL] [Abstract][Full Text] [Related]
14. Enhanced induction of plasma interferon after subcutaneous administration in rabbits of poly ICLC with albumin.
Pessina GP; Muscettola M; Paulesu L; Bocci V
J Biol Regul Homeost Agents; 1989; 3(3):118-21. PubMed ID: 2483023
[TBL] [Abstract][Full Text] [Related]
15. Response of mouse tumor to interferon inducer and radiation.
Lvovsky EA; Mossman KL; Levy HB; Dritschilo A
Int J Radiat Oncol Biol Phys; 1985 Sep; 11(9):1721-5. PubMed ID: 4030439
[TBL] [Abstract][Full Text] [Related]
16. Poly ICLC enhances the antimalarial activity of chloroquine against multidrug-resistant Plasmodium yoelii nigeriensis in mice.
Awasthi A; Mehrotra S; Bhakuni V; Dutta GP; Levy HB; Maheshwari RK
J Interferon Cytokine Res; 1997 Jul; 17(7):419-23. PubMed ID: 9243375
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys.
Kende M; Paragas J; Salazar AM
Antiviral Res; 2019 Mar; 163():179-184. PubMed ID: 30611774
[TBL] [Abstract][Full Text] [Related]
18. Effect of treatment with exogenous interferon, polyriboinosinic-polyribocytidylic acid, or polyriboinosinic-polyribocytidylic acid-poly-L-lysine complex on Herpesvirus hominis infections in mice.
Olsen GA; Kern ER; Overall JC
J Infect Dis; 1978 Apr; 137(4):428-36. PubMed ID: 206632
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor effect of Corynebacterium parvum and poly ICLC on experimental brain tumors].
Kiya K; Kitaoka T; Okamoto H; Harada K; Uozumi T; Toge T; Hattori T; Machida H
Neurol Med Chir (Tokyo); 1983 Nov; 23(11):841-8. PubMed ID: 6201759
[No Abstract] [Full Text] [Related]
20. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta).
Stephen EL; Sammons ML; Pannier WL; Baron S; Spertzel RO; Levy HB
J Infect Dis; 1977 Jul; 136(1):122-6. PubMed ID: 407312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
